Semaglutide: A Promising Ally Against Alzheimer’s?
In a groundbreaking study, researchers at Case Western Reserve School of Medicine have identified a potential new benefit of semaglutide, a widely used diabetes and weight-loss drug. According to their findings, semaglutide may significantly reduce the risk of Alzheimer’s disease in individuals with type 2 diabetes (T2D), outperforming seven other anti-diabetic medications.
Alzheimer’s disease, a devastating brain disorder that erodes memory and cognitive abilities, affects nearly 7 million Americans aged 65 and older, as reported by the Alzheimer’s Association. Alarmingly, it claims more lives annually than breast and prostate cancer combined.
Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the study suggests that T2D patients taking semaglutide had a markedly lower risk of developing Alzheimer’s disease. This trend was consistent across various subgroups, regardless of obesity status, gender, or age.
Semaglutide, a glucagon-like peptide receptor (GLP-1R) agonist, is the active ingredient in popular medications like Wegovy and Ozempic. It works by reducing hunger and regulating blood sugar levels in T2D patients.
Under the leadership of Rong Xu, a professor of biomedical informatics, the research team analyzed three years of electronic health records from nearly one million U.S. patients with T2D. Their statistical approach, which mimicked a randomized clinical trial, revealed that patients prescribed semaglutide had a significantly lower risk of Alzheimer’s compared to those on other anti-diabetic medications.
According to the CDC, Alzheimer’s disease results in approximately 120,000 deaths annually, ranking as the seventh-leading cause of death in the United States.
“This new study provides real-world evidence for semaglutide’s potential impact on Alzheimer’s disease,” Xu stated. “While preclinical research has hinted at its protective effects against neurodegeneration and neuroinflammation, our findings suggest the need for further exploration through randomized clinical trials.”
Despite these promising results, the study’s limitations prevent researchers from drawing definitive causal conclusions. Xu emphasized the importance of continued research into semaglutide’s potential as a treatment for this debilitating condition, encouraging further investigation into alternative drugs.
For more information, please contact Patty Zamora at [email protected].
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
Financial analysis remains one of the strongest career paths for professionals seeking high earnings, steady growth, and long-term stability. With median salaries above $100K, expanding demand across industries, and clear promotion tracks leading to senior leadership roles, the field offers both opportunity and resilience—even as AI reshapes the workplace. This article breaks down what analysts do, salary expectations, job outlook, industry demand, and whether this career is the right fit for you.
After losing their home in the Los Angeles wildfires, Jessica and Matt Conkle expected their insurance policy to help them rebuild. Instead, they found themselves trapped in delays, lowball offers, and endless adjuster changes — a struggle now shared by thousands across California. Their experience highlights a nationwide problem: insurers pulling back from climate‑risk areas, soaring premiums, shrinking coverage, and regulators under fire. For professionals in real estate, mortgage, and insurance, this growing instability is reshaping transactions, lending, risk assessment, and the future of homeownership in America.
Kansas City’s housing market is finally gaining momentum heading into 2026 as falling interest rates, new construction, and a renewed focus on affordable homes open the door for first‑time buyers. Economists say improved supply and softer mortgage rates could shift the market after a challenging 2025, giving real estate professionals and buyers a promising window of opportunity.
Nevada has become the first state to allow insurers to sell homeowners policies without wildfire protection—a move aimed at lowering premiums but raising concerns about consumer risk and mortgage barriers. The law introduces new wildfire‑only policies and a regulatory sandbox for insurance innovation, potentially setting a precedent for other Western states.
Investment groups across the U.S. are rapidly expanding into tax‑deferred real estate programs as demand for Delaware Statutory Trusts (DSTs) accelerates. Major players like Blackstone, Brookfield, Denholtz, and PREP are launching new offerings fueled by stronger market certainty, a historic generational wealth transfer, and renewed confidence in 1031 exchange benefits. As DSTs move into the mainstream, real estate professionals are finding new opportunities to guide clients through advanced tax‑advantaged investment strategies.
Canada’s proptech sector is evolving fast as AI adoption accelerates and investor caution forces startups to mature. Funding has tightened, growth rounds have slowed, and companies are shifting from rapid expansion to profitability and real product‑market fit. AI‑driven platforms like Mave are gaining traction, consolidation is rising, and government housing initiatives may boost construction‑focused tech. For real estate professionals, these trends signal a new industry standard where AI tools and ongoing education are essential to staying competitive.
